Effects of Platelet Rich Fibrin (PRF) in Treatment of Non-healing Sternum Wound After Open-heart Surgery
Launched by SCARM INSTITUTE, TABRIZ, IRAN · Jun 9, 2017
Trial Information
Current as of May 14, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patient has been diagnosed with an acute STEMI or NSTEMI (confirmed by segment elevation (ST) changes on serial ECG, elevated troponin, coronary artery stenosis or occlusion identified by angiography, and a wall motion abnormality identified by angiography or echocardiography)
- • The patient is scheduled to undergo coronary artery bypass surgery.
- • The patient does not possess any contraindication for cardiovascular magnetic resonance (CMR).
- • The patient is capable of giving informed consent.
- • The patient is geographically accessible and willing to return for all follow-up investigations and clinical visits associated with study.
- Exclusion Criteria:
- • The patient is over the age of 65 years.
- • The patient has previous myocardial infarction (MI) (other than the qualifying event) and/or has scar or non-viable myocardium identified by CMR in any other left ventricular (LV) territory.
- • The patient is undergoing other cardiac surgery (i.e. concurrent cardiac valve, or aortic surgery).
- • The patient requires emergency surgery (i.e. operative intervention (CABG or ventricular assist device) within 24-hrs of assessment).
- • The patient has undergone previous cardiac surgery.
- • The patient's postsurgical life expectancy is less than 45 days, in the investigator's opinion.
- • The patient is of excessively poor baseline health, health-related quality of life, or physical functioning that would preclude a reasonable expected post-operative recovery.
- • The patient has received radiotherapy to the chest wall, is receiving immunosuppressive therapy, or is in any way immunocompromised.
About Scarm Institute, Tabriz, Iran
The Scarm Institute, located in Tabriz, Iran, is a leading clinical research organization dedicated to advancing medical science through rigorous clinical trials. With a commitment to ethical research practices and patient safety, the institute specializes in a wide range of therapeutic areas, collaborating with healthcare professionals and innovative pharmaceutical companies to facilitate the development of new treatments. Leveraging state-of-the-art facilities and a team of experienced researchers, Scarm Institute aims to contribute to the global medical community by generating high-quality data that supports regulatory approval and enhances patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tabriz, East Azarbyjan, Iran, Islamic Republic Of
Patients applied
Trial Officials
Mohammad Nouri, Ph.D
Study Chair
Head of SCARM Institute
Ahmad Reza Jodati, CTS
Study Director
SCARM institute
Peyman Keyhanvar, MD, Ph.D
Principal Investigator
Deputy for translational medicine of SCARM institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials